For Some Device Companies, Europe Suddenly Seems Less Inviting
Some device executives have begun to argue that the "Europe first" strategy, whereby device companies being their marketing efforts in Europe, may not be all it's cracked up to be. Adoption ramps up quickly, say some, but only among a handful of leading, innovative clinicians--and then hits a wall, thanks to conservative clinical cultures in many countries.
You may also be interested in...
Data presented at AAAI meeting show reduced annualized asthma exacerbation rates across all patient populations, but doctors are unlikely to switch patients served well by existing biologics.
The RNA drug’s accelerated approval brings Sarepta’s exon-skipping market share to nearly 30%.
Limiting interactions to two-dimensional settings will hinder collaboration, innovation and the mentoring of younger employees, Merck & Co. CEO Kenneth Frazier says. Frazier, who will retire in June, is looking forward to returning to public service but says "politics with a capital P is not my thing."